prochlorperazine (compazine) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Prochlorperazine is a piperazine phenothiazine antipsychotic which block postsynaptic mesolimbic dopaminergic receptors in the brain and has antiemetic effects by its antagonist actions in the D2 dopamine receptors in the chemoreceptor trigger zone. It also exhibits alpha-adrenergic blocking effect on α1 receptros and may depress the release of hypothalamic and hypophyseal hormones. Prochlorperazine is used for the control of severe nausea and vomiting, for the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Prochlorperazine may be an effective treatment of acute headaches and refractory chronic daily headache.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.0406 - $0.7505

United States

$0.3005 - $6.5881
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine | 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine | 3-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine | 3-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine | ant-1401 | buccastem | buccastem m | capazine | chlormeprazine | chloro-3 (n-methylpiperazinyl-3 propyl)-10 phenothiazine | chloropernazine | chlorperazine | compazine | compro | emetiral | meterazin | meterazine | n-(gamma-(4'-methylpiperazinyl-1')propyl)-3-chlorophenothiazine | proazine | prochlorpemazine | prochlorperazin | prochlorperazine | prochlorpérazine | prochlorperazine dimaleate | prochlorperazine edisylate | prochlorperazine ethanedisulfonate | prochlorperazine maleate | prochlorperazine mesilate | prochlorperazine mesylate | prochlorperazinum | prochlorpermazine | prochlorperzine | prochlorpromazine | procloperazine | proclorperazina | procomp | proziere | stemetil eff | vertigon

Organizations (70)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (39)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (5)


 

Anxiety (approved 1959)

Migraine Disorders

Nausea (approved 1959)

Schizophrenia (approved 1959)

Vomiting (approved 1959)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Acute Lung Injury (Phase 1/Phase 2)

Breast Neoplasms (Phase 3)

Cardiotoxicity (Phase 1)

COVID-19 (Phase 1/Phase 2)

Dengue ()

Emergency Service, Hospital (Phase 2)

Epilepsy (Phase 2)

Facial Neuralgia (Phase 3)

Genital Neoplasms, Female (Phase 3)

Headache (Phase 4)

Headache Disorders, Primary (Phase 2)

Healthy Volunteers (Phase 1)

Laparoscopy (Phase 4)

Migraine Disorders (Phase 4)

Migraine with Aura (Phase 2)

Multiple Myeloma (Early Phase 1)

Nausea (Phase 4)

Neoplasms (Phase 3)

Pain Management (Phase 2)

Pneumonia (Phase 1/Phase 2)

Respiratory Distress Syndrome (Phase 1/Phase 2)

Rhytidoplasty (Phase 2)

Vertigo (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue